GlassScriptPhysician profile
Mary Eversole
NPI 1669805578
$1,380.65
in general payments reported to CMS, 2019-2025
25 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.61 · 2022: $15.78 · 2023: $10.45 · 2024: $527 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $154.48 | 2024-2025 | Farxiga, Brilinta, Wainua |
| Novartis Pharmaceuticals Corporation | $144.26 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.08 | 2021-2025 | Lifevest |
| Pfizer INC. | $101.87 | 2024-2025 | |
| Abiomed | $96.86 | 2025 | |
| Novo Nordisk INC | $87.18 | 2024-2025 | Ozempic |
| Kestra Medical Technology Services, INC. | $86.01 | 2024-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $80.92 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.04 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $67.32 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.24 | 2022-2024 | Jardiance |
| Abbott Laboratories | $40.69 | 2024 | Cardiomems |
| Merck Sharp & Dohme LLC | $35.50 | 2024-2025 | Verquvo |
| Amgen INC. | $34.73 | 2024-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $31.65 | 2024-2025 | Opsumit, Uptravi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.41 | 2025 | |
| Alnylam Pharmaceuticals INC. | $28.69 | 2024 | Onpattro |
| Daiichi Sankyo INC. | $19.90 | 2025 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $17.98 | 2024 | |
| Glaxosmithkline, LLC. | $17.54 | 2025 | Arexvy, Shingrix |
| Mannkind Corporation | $16.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $16.71 | 2024 | Xarelto |
| Chiesi USA, INC. | $15.32 | 2025 | Cleviprex, Kengreal |
| Lilly USA, LLC | $14.90 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $14.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Eversole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.